Evidence map›Paper›PMID 38031086›Full record

SynthesisTrials2023

Master statistical analysis plan: attractive targeted sugar bait phase III trials in Kenya, Mali, and Zambia.

Joshua Yukich, Thomas P Eisele, Feiko terKuile, Ruth Ashton, Sarah Staedke, Angela F Harris, Paul C D Johnson, Sophie Sarrassat, Maia Lesosky, John Bradley and 3 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Joshua YukichTulane University School of Public Health and Tropical Medicine, New Orleans, USA. jyukich@tulane.edu.ORCID http://orcid.org/0000-0002-6160-5295
Thomas P EiseleTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
Feiko terKuileTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
Ruth AshtonTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
Sarah StaedkeTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
Angela F HarrisTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
Paul C D JohnsonTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
Sophie SarrassatTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
Maia LesoskyTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
John BradleyTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
Immo KleinschmidtTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
Megan LittrellTulane University School of Public Health and Tropical Medicine, New Orleans, USA.
Attractive Targeted Sugar Bait Phase III Trial Group
Tulane University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This manuscript is a master statistical analysis plan for each of three-cluster randomized controlled trials to evaluate the efficacy of attractive targeted sugar baits (ATSB) described in an already published protocol. The master SAP contains an overarching plan for all three trials, which can be adapted to trial-specific circumstances. The primary objective of the trials is to evaluate the efficacy of ATSB in the presence of universal vector control coverage with insecticide-treated nets (ITN) or indoor residual spraying (IRS) after two transmission seasons on clinical malaria incidence as compared with universal vector control coverage with ITN or IRS alone. The primary outcome measure is the incidence rate of clinical malaria, assessed in cohorts aged 12 months to less than 15 years (≥ 5 years to 15 years in Mali) during monthly follow-up visits. The primary unadjusted analysis will be conducted on the intention-to-treat analysis population without adjustment for any anticipated confounding variables. The primary outcome will be analyzed using a multi-level model constructed on a generalized linear model framework with a Poisson likelihood and a log link function. Random intercepts will be included for each study cluster and a fixed effect for study-arm. The analyst will be blinded to study arm assignment. Several secondary outcomes will be analyzed, as well as a pooled analysis (individual patient data meta-analysis) across the three trial sites. Additionally, a standard meta-analysis is expected to be conducted using combined data from all sites.

Indexed as

InsecticidesInsecticide-Treated BednetsMalariaClinical Trials, Phase III as TopicHumansKenyaMaliMosquito ControlSugarsZambiaInsecticidesSugarsCluster randomized control trialMalariaStatistical analysis planVector control

Identifiers

PMID38031086
PMCPMC10685482
OpenAlexW4389143930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.